This study provided visual demonstrations of weight loss and health risk improvement with tirzepatide as a dual GIP and GLP-1 receptor agonist. The patient-facing visualization tool helps communicate treatment benefits.
Ramirez, Sophia; Yang, Ryan; Habibovic, Muhammed; Kennedy, Samantha; Bennett, Jonathan P; Shepherd, John A; Thomas, Diana M; Heymsfield, Steven B